ES2254046T1 - Tratamiento de hiperplasia prostatica benigna. - Google Patents

Tratamiento de hiperplasia prostatica benigna.

Info

Publication number
ES2254046T1
ES2254046T1 ES04702967T ES04702967T ES2254046T1 ES 2254046 T1 ES2254046 T1 ES 2254046T1 ES 04702967 T ES04702967 T ES 04702967T ES 04702967 T ES04702967 T ES 04702967T ES 2254046 T1 ES2254046 T1 ES 2254046T1
Authority
ES
Spain
Prior art keywords
lonidamine
treatment
bph
approximately
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
ES04702967T
Other languages
English (en)
Spanish (es)
Inventor
George Tidmarsh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Molecular Templates Inc
Original Assignee
Threshold Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Threshold Pharmaceuticals Inc filed Critical Threshold Pharmaceuticals Inc
Publication of ES2254046T1 publication Critical patent/ES2254046T1/es
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/342—Prostate diseases, e.g. BPH, prostatitis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
ES04702967T 2003-01-17 2004-01-16 Tratamiento de hiperplasia prostatica benigna. Pending ES2254046T1 (es)

Applications Claiming Priority (19)

Application Number Priority Date Filing Date Title
US44111003P 2003-01-17 2003-01-17
US441110P 2003-01-17
US44234403P 2003-01-23 2003-01-23
US442344P 2003-01-23
US45866503P 2003-03-28 2003-03-28
US45866303P 2003-03-28 2003-03-28
US45884603P 2003-03-28 2003-03-28
US458663P 2003-03-28
US458846P 2003-03-28
US458665P 2003-03-28
US46001203P 2003-04-02 2003-04-02
US460012P 2003-04-02
US47290703P 2003-05-22 2003-05-22
US472907P 2003-05-22
US48826503P 2003-07-18 2003-07-18
US488265P 2003-07-18
US49616303P 2003-08-18 2003-08-18
US496163P 2003-08-18
PCT/US2004/001141 WO2004064735A2 (en) 2003-01-17 2004-01-16 Treatment of benign prostatic hyperplasia

Publications (1)

Publication Number Publication Date
ES2254046T1 true ES2254046T1 (es) 2006-06-16

Family

ID=32777423

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04702967T Pending ES2254046T1 (es) 2003-01-17 2004-01-16 Tratamiento de hiperplasia prostatica benigna.

Country Status (13)

Country Link
US (4) US6989400B2 (enExample)
EP (2) EP1610778A4 (enExample)
JP (2) JP2006518343A (enExample)
KR (2) KR20050098250A (enExample)
AU (2) AU2004206870A1 (enExample)
BR (1) BRPI0406796A (enExample)
CA (2) CA2513572A1 (enExample)
DE (1) DE04702967T1 (enExample)
ES (1) ES2254046T1 (enExample)
IL (1) IL169685A0 (enExample)
MX (2) MXPA05007571A (enExample)
NO (1) NO20053783L (enExample)
WO (2) WO2004064735A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7547673B2 (en) * 2001-09-13 2009-06-16 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of ATP production
US7524885B2 (en) * 2002-04-01 2009-04-28 The Governors Of The University Of Alberta Compounds that stimulate glucose utilization and methods of use
WO2004064735A2 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia
WO2006091790A1 (en) 2005-02-23 2006-08-31 Xenoport, Inc. Platinum-containing compounds exhibiting cytostatic activity, synthesis and methods of use
US20060287253A1 (en) * 2005-06-17 2006-12-21 Kriegler Steven M Compounds and methods for treating seizure disorders
US8324175B2 (en) 2006-02-16 2012-12-04 Young Hee Ko Compositions and methods for the treatment of cancer
WO2007101148A2 (en) * 2006-02-24 2007-09-07 Board Of Regents, The University Of Texas System Hexose compounds to treat cancer
CA2644809A1 (en) 2006-03-02 2007-09-07 Astellas Pharma Inc. 17 .beta. hsd type 5 inhibitor
WO2008076964A1 (en) * 2006-12-18 2008-06-26 The Johns Hopkins University Therapeutics for cancer using 3-bromopyruvate and other selective inhibitors of atp production
US20080245375A1 (en) * 2007-04-05 2008-10-09 Medtronic Vascular, Inc. Benign Prostatic Hyperplasia Treatments
WO2009014150A1 (ja) 2007-07-24 2009-01-29 Astellas Pharma Inc. ベンズイミダゾール誘導体
SI2181990T1 (sl) 2007-08-31 2012-10-30 Astellas Pharma Inc Piperidinski derivat
US8603123B2 (en) 2008-04-28 2013-12-10 Urotech, Inc. Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration
DK2331092T3 (da) 2008-08-21 2014-05-19 Univ Johns Hopkins Fremgangsmåder og sammensætninger til indgivelse af 3-halopyruvat og associerede forbindelser til behandling af cancer
AU2010208062B2 (en) * 2009-01-29 2014-07-24 Kodiscovery, Llc Compositions and methods for the treatment of cancer
WO2013153821A1 (ja) * 2012-04-12 2013-10-17 Omura Satoshi Ｐｄｋ４阻害剤及びその利用
US10441561B2 (en) 2012-07-26 2019-10-15 The William M. Yanbrough Foundation Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer
JP6552509B2 (ja) 2014-01-14 2019-07-31 ザ・ジョンズ・ホプキンス・ユニバーシティー 選択的ａｔｐ阻害剤をカプセル化するシクロデキストリン組成物およびその使用
WO2017079563A1 (en) 2015-11-06 2017-05-11 The Johns Hopkins University Methods of treating liver fibrosis by administering 3-bromopyruvate
EP3564214B1 (en) 2018-05-04 2024-07-03 Universita' Degli Studi G. D'annunzio Chieti - Pescara Indazole derivatives as modulators of the cannabinoid system
CN116438162A (zh) * 2020-09-17 2023-07-14 伊赛恩特制药公司 Mas相关g蛋白受体x4的调节剂及相关产物和方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1052111B (it) * 1972-02-29 1981-06-20 Acraf Acidi i benzil i h indazol 3 carbossilici sostituiti e loro derivati
US4684627A (en) * 1981-09-08 1987-08-04 Leveen Harry H Treatment of cancer with phlorizin and its derivatives
CA1289077C (en) * 1984-08-13 1991-09-17 Harry H. Leveen Treatment of cancer with phlorizin and its derivatives
US5260327A (en) * 1985-10-02 1993-11-09 Sloan-Kettering Institute For Cancer Research Methods for inhibiting the proliferation of brain and hepatic metastases by using lonidamine
WO1992018132A1 (en) * 1991-04-17 1992-10-29 Merck & Co., Inc. Pharmaceutical combination for the treatment of benign prostatic hyperplasia comtaining a 5 alpha-reductase inhibitor
US6063911A (en) * 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
US5654320A (en) * 1995-03-16 1997-08-05 Eli Lilly And Company Indazolecarboxamides
SK72996A3 (en) 1995-06-07 1997-04-09 Pfizer Heterocyclic ring-fused pyrimidine derivatives and pharmaceutical compositions on their base
FR2737721B1 (fr) * 1995-08-08 1997-09-05 Roussel Uclaf Nouveaux composes biphenyles, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicament et les compositions pharmaceutiques les contenant
ATE202551T1 (de) 1995-10-18 2001-07-15 Kanoldt Arzneimittel Gmbh Lignane, verfahren zu ihrer herstellung, ihre pharmazeutische compositionen und anwendungen
DE19621319A1 (de) 1996-05-28 1997-12-04 Hoechst Ag Bis-ortho-substituierte Benzoylguanidine, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament
US6054432A (en) 1996-09-12 2000-04-25 Asta Medica Aktiengesellschaft Means for treating prostate hypertrophy and prostate cancer
IT1289938B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
IT1289939B1 (it) * 1997-02-20 1998-10-19 Angelini Ricerche Spa Composizione farmaceutica acquosa comprendente un principio attivo altamente insolubile in acqua
CN1078462C (zh) * 1997-07-09 2002-01-30 辛国芳 棉酚和/或其衍生物作为有效成分在制备用于治疗前列腺炎的栓剂中的应用
EP1083896A4 (en) * 1998-05-11 2002-09-11 Endowment For Res In Human Bio USE OF NEOMYCIN FOR TREATING ANGIOGENESIS-RELATED DISEASES
US6428968B1 (en) * 1999-03-15 2002-08-06 The Trustees Of The University Of Pennsylvania Combined therapy with a chemotherapeutic agent and an oncolytic virus for killing tumor cells in a subject
US6001865A (en) * 1999-05-04 1999-12-14 Angelini Pharmaceuticals Inc. 3-substituted 1-benzyl-1H-indazole derivatives as antifertility agents
WO2004064735A2 (en) 2003-01-17 2004-08-05 Threshold Pharmaceuticals, Inc. Treatment of benign prostatic hyperplasia
SG151299A1 (en) * 2004-03-25 2009-04-30 Univ Michigan Gossypol co-crystals and the use thereof

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795227B2 (en) 2004-06-17 2010-09-14 Wisconsin Alumni Research Foundation Compounds and methods for treating seizure disorders

Also Published As

Publication number Publication date
AU2004206870A1 (en) 2004-08-05
JP2006518343A (ja) 2006-08-10
US20050272796A1 (en) 2005-12-08
MXPA05007571A (es) 2005-11-17
WO2004064736A2 (en) 2004-08-05
AU2004206869A1 (en) 2004-08-05
US20050271723A1 (en) 2005-12-08
NO20053783D0 (no) 2005-08-09
US20040167196A1 (en) 2004-08-26
MXPA05007572A (es) 2005-11-17
KR20050098249A (ko) 2005-10-11
BRPI0406796A (pt) 2006-01-17
EP1592430A2 (en) 2005-11-09
EP1592430A4 (en) 2006-05-31
JP2006516571A (ja) 2006-07-06
US6989400B2 (en) 2006-01-24
IL169685A0 (en) 2007-07-04
US20050272795A1 (en) 2005-12-08
WO2004064735A3 (en) 2004-12-16
WO2004064736A3 (en) 2005-05-06
NO20053783L (no) 2005-09-27
CA2513572A1 (en) 2004-08-05
EP1610778A2 (en) 2006-01-04
EP1610778A4 (en) 2006-05-31
DE04702967T1 (de) 2006-06-22
CA2513575A1 (en) 2004-08-05
KR20050098250A (ko) 2005-10-11
WO2004064735A2 (en) 2004-08-05

Similar Documents

Publication Publication Date Title
ES2254046T1 (es) Tratamiento de hiperplasia prostatica benigna.
Robard et al. Medical treatment of osteoradionecrosis of the mandible by PENTOCLO: preliminary results
Lim et al. A comparative study on the efficacy of submucosal injection of dexamethasone versus methylprednisolone in reducing postoperative sequelae after third molar surgery
US20220016246A1 (en) Hypertonic antimicrobial therapeutic compositions
de Oliveira et al. Comparative assessment of the effect of ibuprofen and etodolac on edema, trismus, and pain in lower third molar surgery: a randomized clinical trial
RU2010140682A (ru) Способ лечения пациента от инфекции, фармацевтическая композиция (варианты) и лекарственное средство
JP2006516571A5 (enExample)
CL2024001530A1 (es) Nuevas combinaciones terapéuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
CL2024003616A1 (es) Composición farmacéutica oral y uso para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
CO2023000516A2 (es) Composiciones de dosis orales unitarias compuestas de ibuprofeno y famotidina para el tratamiento de dolor agudo y la reducción de la gravedad yo riesgo de acidez estomacal referencia cruzada a solicitudes relacionadas
Giammarinaro et al. Local formula with mucoadhesive property: a randomized clinical trial of a therapeutic agent for the treatment of oral aphthous ulcers
Leone et al. Comparison of methylprednisolone and ketoprofen after multiple third molar extraction: a randomized controlled study
Baurmash et al. The nonsurgical treatment of hemangioma with Sotradecol
Dayanarayana et al. Non surgical approaches in treatment of OSF
Managutti et al. Evaluation of clinical efficacy of Cissus quadrangularis in pain management and bone healing after implant placement: A pilot study
Merchant et al. Comparative evaluation of clinical efficacy of hyaluronic acid spray versus normal saline spray on swelling, pain, and trimus after surgical extraction of impacted mandibular third molar–a randomized controlled split mouth study
Scotti et al. Anti-inflammatory and wound healing effects of an essential oils-based bioadhesive gel after oral mucosa biopsies: preliminary results
RU2005131578A (ru) Аплидин для лечения множественной миеломы
Trombelli et al. Effect of pretreatment with ketorolac tromethamine on post‐operative pain following periodontal surgery
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
Zamiri et al. Comparison of ibuprofen, celecoxib and tramadol in relief of pain after extraction of mandibular third molar teeth
Jarrah et al. Single dose of dexamethasone with or without ibuprofen effects on post-operative sequelae of lower third molar surgical extraction
Levine et al. A novel treatment of gingival recession using a botanical topical gingival patch and mouthrinse
Shubhavinyasa et al. Palliative care in patients with oral cancer